Skip Navigation


JAC Advance Access originally published online on June 12, 2003
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
52/1/138    most recent
dkg289v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (34)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Cercenado, E.
Right arrow Articles by Bouza, E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Cercenado, E.
Right arrow Articles by Bouza, E.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?


Journal of Antimicrobial Chemotherapy (2003) 52, 138-139
© 2003 The British Society for Antimicrobial Chemotherapy

Correspondence

In vitro activity of tigecycline (GAR-936), a novel glycylcycline, against vancomycin-resistant enterococci and staphylococci with diminished susceptibility to glycopeptides

Emilia Cercenado*, Sonia Cercenado, Juan A. Gómez and Emilio Bouza

Servicio de Microbiología, Hospital General Universitario ‘Gregorio Marañón’, Dr. Esquerdo 46, 28007 Madrid, Spain

Keywords: tigecycline, GAR-936, glycopeptide-resistant enterococci, glycopeptide-resistant staphylococci, Gram-positives

The first 10% of the full text of this article appears below.

Sir,

Increasing antimicrobial resistance among clinical isolates of staphylococci and enterococci has complicated the treatment of infections caused by these microorganisms, and there is a need for therapeutic alternatives against them. The glycylcyclines are novel tetracycline analogues with activity against Gram-positive and Gram-negative aerobic and anaerobic bacteria, including tetracycline-resistant isolates. The glycylcycline tigecycline (GAR-936) is active against a variety of microorganisms;1–3 however, information concerning its activity against glycopeptide-resistant enterococci is very scarce, and there is none about its activity against staphylococci with diminished susceptibility . . . [Full Text of this Article]

Acknowledgements


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 J Antimicrob ChemotherHome page
G. A. Pankey
Tigecycline
J. Antimicrob. Chemother., September 1, 2005; 56(3): 470 - 480.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Microbiol.Home page
P. G. Scapellato, C. Ormazabal, J. L. Scapellato, and E. G. Bottaro
Meningitis Due to Vancomycin-Resistant Enterococcus faecium Successfully Treated with Combined Intravenous and Intraventricular Chloramphenicol
J. Clin. Microbiol., July 1, 2005; 43(7): 3578 - 3579.
[Full Text] [PDF]